Want to see EW full AI Analyst Report?
Revenue by Segment
Breaks down sales by business line—such as transcatheter devices, surgical products, and monitoring systems—revealing which segments drive growth and profitability. Shifts in segment mix indicate where innovation, pricing power, or recurring consumables are strongest, and where the company is deploying capital to scale future revenue.Edwards is increasingly a structural-heart story: TAVR remains the clear cash engine with steady acceleration into 2026, Surgical Structural Heart is a stable but slower grower, and Transcatheter Mitral & Tricuspid is the breakout high‑growth area—moving from a token line item to meaningful revenue, signaling early commercial traction. The abrupt disappearance of Critical Care after Q1 2024 reflects a divestiture or reporting change that narrows revenue diversification and raises concentration risk—good for margin focus if procedure volumes hold, risky if structural-heart demand softens.
Date | Transcatheter Aortic Valve Replacement | Transcatheter Mitral and Tricuspid Therapies | Surgical Structural Heard | Critical Care |
|---|---|---|---|---|
Jun 30, 2026 | $1.26B | $198.60M | $284.10M | $0.00 |
Mar 31, 2026 | $1.20B | $175.10M | $276.20M | $0.00 |
Dec 31, 2025 | $1.16B | $155.70M | $253.60M | $0.00 |
Sep 30, 2025 | $1.15B | $145.20M | $258.00M | $0.00 |
Jun 30, 2025 | $1.13B | $134.50M | $266.80M | $0.00 |
Mar 31, 2025 | $1.05B | $115.20M | $250.90M | $0.00 |
Dec 31, 2024 | $1.04B | $105.10M | $244.40M | $0.00 |
Sep 30, 2024 | $1.02B | $91.10M | $240.00M | $0.00 |
Jun 30, 2024 | $1.04B | $83.00M | $264.30M | $0.00 |
Mar 31, 2024 | $1.01B | $72.90M | $266.10M | $251.30M |